It just hit me at 3:00 Am.

The Abbott / Biocurex revised arrangement is similar to the Biocurex / note holders revised arrangement.

Abbott was not ready to go live with the Lung cancer test until The patents were tested/approved etc. (This was a huge undertaking) They went to Biocurex and said...Your part of the panel of markers works fine now...We need you to hold off for x time till we can get this gargantuan panel of tests up and running so that we can commercialize it. In return for waiting almost x years...We will increase your royalties when the test comes out. Also since Recaf is your only product, You can have your manual tests to turn a profit in the mean time...While manual tests can benefit a small company such as Biocurex in the short, They will hardly effect our (Abbott) profits when the big automated test comes out.

Note: We had all thought we were going to see a stand alone test for just Recaf for cancer. this was never the thinking at Abbott. They did want Recaf badly but it was for a multi panel test.

We will probably see another such test in the next months...Years... for Prostate and Ovarian etc. Coming out of Abbott.

First things are first though. Get the Lung test up and running...Then go for the next set.

What was Biocurex going to say? No we are not interested in waiting....The only answer was ok we understand.

This is the same as our agreement with the note holders. They said we want our money...Biocurex said hold on we are so close we can taste it. Hence an agreement was made...No payments for x months The money is coming but we are waiting on this mass test to come out. In the mean time we are progressing with our manual test in China that will get us through till the mass test hits the street. Just as Abbott will increase our royaltees...So will we be paying more interest to the note holders.

Just a pure Guess on my part...But it works for me.